August 24, 2021 5:36pm

The Biostage (BSTG) Chronicles: WHERE is the SEC? Another 15,777 shares were traded to prop the $2.05 (+$0.16) share price after Monday’s 38,354 shares (+$0.68 to $1.89) traded following months of 100 to 1,100 daily trading volume. Is it all about exercising $2.00 warrants from multiple private placements to raise any cash for a clinical trial (with an IND aged by 1.5 years) that never began?

Pre-open indications: 1 MISS and 5 HITs

My comments try to distinguish the temporary from real pricing digression or progress.

Who else is tracking a broad representative index of cell and gene therapy equities – the facts are supported by real numbers?

 

The Dow closed UP +30.55 points (+0.09%); the S&P closed UP +6.70 points (+0.15%) while the Nasdaq closed UP +77.15 points (+0.52%)

 

Henry’omics:

Indexes were slightly higher Tuesday following news that U.S. regulators granted full approval for Pfizer-BioNTech’s Covid vaccine.

Cell and gene therapy small caps were “better than anticipated” performers of the day compared to yesterday with the Russell 2000 finished with today’s gain of 1% after it fell more than 2% last week.

The U.S. SEC said it plans to demand U.S.-traded Chinese companies disclose political and regulatory risks to investors

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Tuesday opened negative at 16/18 and 1 acquired, stayed negative at the mid-day at 15/17, 2 flats and 1 acquired, ending with a positive close of 21/13, 1 flat and 1 acquired;
  • Monday opened positive at 32/2 and 1 acquired, remained positive at the mid-day to 8/24, 2 flats and 1 acquired, closing positive 32/1, 1 flat and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “skim the upside moves while one can. If I have learned one thing as a former research analyst i.e., venture and public markets investor and a consultant to an ever-evolving journalist and pundit; it is that your life and your portfolio are largely tied to asking and getting answers to questions.” … https://www.regmedinvestors.com/articles/12063

 

The Biostage (BSTG) Chronicles: “Facts from filed 10-Q” … https://www.regmedinvestors.com/articles/12055

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

  • Net Income: 3 and Net losses: 23

 

Key Metrics:

  • Sector volume was LOW with 3 of the 21-upside having higher than the 3-month average volume with very LOW volume of 1 of 12-downside having higher than the 3-month average volume;
  • Tuesday’s percentage (%) of the 21-upside were +0.38% (VCEL) to +9.21% (BLCM) while the 12-downside -0.41% (RGNX) to -3.95% (PGEN);

 

The Biostage (BSTG) Chronicles: Tuesday closed up +$0.28 with 10,590 shares trade after Monday’s +$0.68 with 38,354 shares traded following Friday’s -$0.07 with 570 shares traded, Thursday’s flat at with 50 shares traded, and Wednesday’s closing down -$0.10 with 739 shares traded as last Tuesday closed flat with 1 share traded.

  • Today is just another fact, how the share trades with the “push/promote” - another typical example

 

Pre-open Indications: 4 HITs <SELL into Strength: Ionis Pharmaceuticals (IONS +$0.95); Cellectis SA (CLLS -$0.21), Editas Medicine (EDIT -$0.64), CRISPR Therapeutics (CTSP +$1.44), > 2 MISS < Biostage (BSTG +$0.28), Intellia Therapeutics (NTLA +$4.76>;

 

There are clear winners and losers

Jumping with share pricing momentum:

  • Intellia Therapeutics (NTLA) – another again, Alnylam Pharmaceuticals (ALNY), Ultragenyx (RARE) – another again, CRISPR Therapeutics (CRSP) – another again, Ionis Pharmaceuticals (IONS) to name 5 of the 21 inclining of the 35 covered

Hammered in today’s market:

  • ReNeuron (RENE.L), Fate Therapeutics (FATE), Editas Medicine (EDIT), BioLife Solutions (BLFS), Precigen (PGEN), Cellectis SA (CLLS) to name 5 of the 12 declining of the 35 covered

 

Tuesday’s (10 of 21) incliners:

  • Intellia Therapeutics (NTLA +$4.28 after Monday’s +$8.75);
  • Alnylam Pharmaceuticals (ALNY +$3.50);
  • Ultragenyx (RARE +$2.73 after Monday’s +$4.49);
  • CRISPR Therapeutics (CRSP +$1.44 after Monday’s +$7.80);
  • Ionis Pharmaceuticals (IONS +$0.95 after Monday’s -$0.23);
  • Global Blood Therapeutics (GBT +$0.56 after Monday’s +$1.18);
  • Sage Therapeutics (SAGE +$0.31);
  • Bellicum Pharmaceuticals (BLCM +$0.28);
  • MiMedx (MDXG +$0.27);
  • Vericel (VCEL +$0.20 after Monday’s +$2.31),

Tuesday’s (12 of 12) decliners:

  • ReNeuron (RENE.L -$1.50);
  • Fate Therapeutics (FATE -$0.74 after Monday’s +$5.26);
  • Editas Medicine (EDIT -$0.64 after Monday’s +$4.98);
  • BioLife Solutions (BLFS -$0.27 after Monday’s +$1.38);
  • Precigen (PGEN -$0.24);
  • Cellectis SA (CLLS -$0.21);
  • AxoGen (AXGN -$0.19);
  • bluebird bio (BLUE -$0.15);
  • Regenxbio (RGNX -$0.13 after Monday’s +$2.13);
  • Sangamo Therapeutics (SGMO -$0.13);
  • Athersys (ATHX -$0.03);
  • Verastem (VSTM -$0.02);

Closing – 1 –Adverum Biotechnologies (ADVM) and 1 -Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB closed down -0.28% and XBI closed up +0.01%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was up +0.07 points or +0.41% at 17.22

Upside volume:

  • Tuesday:  3 out of the 21-upside had higher than the 3-month average volume;

Downside volume:

  • Tuesday: 1 out of the 12-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: price versus percentage …

  • Tuesday’s percentage (%) of the 21-upside were +0.38% (VCEL) to +9.21% (BLCM) while the 12-downside -0.41% (RGNX) to -3.95% (PGEN);

 

August, the second month of Q3/21:

  • Tuesday closed positive with 21 advancers, 12 decliners, 1 flat and 1 acquired
  • Monday (8/23) closed positive with 32 advancers, 1 decliner, 1 flat and 1 acquired

 

The BOTTOM LINE: As I had stated, “Investor conviction and any trust is being challenged even as the sector rises, I believe a “conflagration” is coming” – it seems to be started …

Reiterating, being overbought set-up another “SELLING “condition”.

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started.

Q2 reporting season has essentially run its course; although a few remain with my questions of WHY so late …?

A tool that hasn’t resonated … guidance is one factor of the sector.

I am keeping an eye on “runways” … as 2024 seems to be timing factor for most.

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.